Immune response markers in sentinel nodes may predict melanoma progression

Abstract

We recently reported that variable expression of immune-response genes distinguishes tumor positive sentinel nodes in melanoma patients with malignant progression from those with non-progressing disease. Our results depict sentinel nodes as sites in which immune functions are associated with metastatic disease and identify CD30 as a host immune-related cancer prognostic marker and potential therapeutic target.

Keywords: :

• sentinel node
• melanoma
• expression profiles
• CD30
• lymph node

Citation: Rodolfo M, Castelli C, Rivoltini L. Immune response markers in sentinel nodes may predict melanoma progression. OncoImmunology 2014; 3:e28498; 10.4161/onci.28498

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.